Surgical results of resectable small cell lung cancer

Daigo Kawano, Tatsuro Okamoto, Takatoshi Fujishita, Yuzo Suzuki, Hirokazu Kitahara, Shinichiro Shimamatsu, Yoshihiko Maehara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. Methods: The records of 57 LD SCLC patients who underwent surgical resection from April 1974 to March 2012 were retrospectively analyzed. Results: There were six women and 51 men, with a median age of 63.5 years. The overall five-year survival rate was 28.6% (median, 18.2 months). The p-stage II and III patients had a significantly worse survival than the p-stage I patients (13.4% vs. 43.4%, P = 0.0036). However, the c-stage was not found to correlate with survival. Patients who underwent pneumonectomy had a significantly worse outcome than those who underwent other surgical procedures (0.0% vs. 32.0%, P = 0.0002). In a multivariate Cox proportional hazards analysis, p-stage II or III (hazard ratio [HR] 3.040 P = 0.0017) and pneumonectomy (HR 6.177, P = 0.00159) were significant independent predictors of an adverse survival outcome. Conclusions: Surgical treatment can be considered in SCLC patients with pathologically proven N0 status, although pneumonectomy should be avoided.

Original languageEnglish
Pages (from-to)141-145
Number of pages5
JournalThoracic Cancer
Volume6
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Small Cell Lung Carcinoma
Pneumonectomy
Survival
Standard of Care
Radiotherapy
Survival Rate
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Kawano, D., Okamoto, T., Fujishita, T., Suzuki, Y., Kitahara, H., Shimamatsu, S., & Maehara, Y. (2015). Surgical results of resectable small cell lung cancer. Thoracic Cancer, 6(2), 141-145. https://doi.org/10.1111/1759-7714.12154

Surgical results of resectable small cell lung cancer. / Kawano, Daigo; Okamoto, Tatsuro; Fujishita, Takatoshi; Suzuki, Yuzo; Kitahara, Hirokazu; Shimamatsu, Shinichiro; Maehara, Yoshihiko.

In: Thoracic Cancer, Vol. 6, No. 2, 01.03.2015, p. 141-145.

Research output: Contribution to journalArticle

Kawano, D, Okamoto, T, Fujishita, T, Suzuki, Y, Kitahara, H, Shimamatsu, S & Maehara, Y 2015, 'Surgical results of resectable small cell lung cancer', Thoracic Cancer, vol. 6, no. 2, pp. 141-145. https://doi.org/10.1111/1759-7714.12154
Kawano D, Okamoto T, Fujishita T, Suzuki Y, Kitahara H, Shimamatsu S et al. Surgical results of resectable small cell lung cancer. Thoracic Cancer. 2015 Mar 1;6(2):141-145. https://doi.org/10.1111/1759-7714.12154
Kawano, Daigo ; Okamoto, Tatsuro ; Fujishita, Takatoshi ; Suzuki, Yuzo ; Kitahara, Hirokazu ; Shimamatsu, Shinichiro ; Maehara, Yoshihiko. / Surgical results of resectable small cell lung cancer. In: Thoracic Cancer. 2015 ; Vol. 6, No. 2. pp. 141-145.
@article{282c4bed3c3641058f5937ff4b734333,
title = "Surgical results of resectable small cell lung cancer",
abstract = "Background: The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. Methods: The records of 57 LD SCLC patients who underwent surgical resection from April 1974 to March 2012 were retrospectively analyzed. Results: There were six women and 51 men, with a median age of 63.5 years. The overall five-year survival rate was 28.6{\%} (median, 18.2 months). The p-stage II and III patients had a significantly worse survival than the p-stage I patients (13.4{\%} vs. 43.4{\%}, P = 0.0036). However, the c-stage was not found to correlate with survival. Patients who underwent pneumonectomy had a significantly worse outcome than those who underwent other surgical procedures (0.0{\%} vs. 32.0{\%}, P = 0.0002). In a multivariate Cox proportional hazards analysis, p-stage II or III (hazard ratio [HR] 3.040 P = 0.0017) and pneumonectomy (HR 6.177, P = 0.00159) were significant independent predictors of an adverse survival outcome. Conclusions: Surgical treatment can be considered in SCLC patients with pathologically proven N0 status, although pneumonectomy should be avoided.",
author = "Daigo Kawano and Tatsuro Okamoto and Takatoshi Fujishita and Yuzo Suzuki and Hirokazu Kitahara and Shinichiro Shimamatsu and Yoshihiko Maehara",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/1759-7714.12154",
language = "English",
volume = "6",
pages = "141--145",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "2",

}

TY - JOUR

T1 - Surgical results of resectable small cell lung cancer

AU - Kawano, Daigo

AU - Okamoto, Tatsuro

AU - Fujishita, Takatoshi

AU - Suzuki, Yuzo

AU - Kitahara, Hirokazu

AU - Shimamatsu, Shinichiro

AU - Maehara, Yoshihiko

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background: The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. Methods: The records of 57 LD SCLC patients who underwent surgical resection from April 1974 to March 2012 were retrospectively analyzed. Results: There were six women and 51 men, with a median age of 63.5 years. The overall five-year survival rate was 28.6% (median, 18.2 months). The p-stage II and III patients had a significantly worse survival than the p-stage I patients (13.4% vs. 43.4%, P = 0.0036). However, the c-stage was not found to correlate with survival. Patients who underwent pneumonectomy had a significantly worse outcome than those who underwent other surgical procedures (0.0% vs. 32.0%, P = 0.0002). In a multivariate Cox proportional hazards analysis, p-stage II or III (hazard ratio [HR] 3.040 P = 0.0017) and pneumonectomy (HR 6.177, P = 0.00159) were significant independent predictors of an adverse survival outcome. Conclusions: Surgical treatment can be considered in SCLC patients with pathologically proven N0 status, although pneumonectomy should be avoided.

AB - Background: The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. Methods: The records of 57 LD SCLC patients who underwent surgical resection from April 1974 to March 2012 were retrospectively analyzed. Results: There were six women and 51 men, with a median age of 63.5 years. The overall five-year survival rate was 28.6% (median, 18.2 months). The p-stage II and III patients had a significantly worse survival than the p-stage I patients (13.4% vs. 43.4%, P = 0.0036). However, the c-stage was not found to correlate with survival. Patients who underwent pneumonectomy had a significantly worse outcome than those who underwent other surgical procedures (0.0% vs. 32.0%, P = 0.0002). In a multivariate Cox proportional hazards analysis, p-stage II or III (hazard ratio [HR] 3.040 P = 0.0017) and pneumonectomy (HR 6.177, P = 0.00159) were significant independent predictors of an adverse survival outcome. Conclusions: Surgical treatment can be considered in SCLC patients with pathologically proven N0 status, although pneumonectomy should be avoided.

UR - http://www.scopus.com/inward/record.url?scp=84923698760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923698760&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.12154

DO - 10.1111/1759-7714.12154

M3 - Article

AN - SCOPUS:84923698760

VL - 6

SP - 141

EP - 145

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

IS - 2

ER -